A Phase II Double-blind, Placebo-controlled, Randomized Trial of Topical Artesunate Ointment for the Treatment of Patients With Vulvar High-grade Squamous Intraepithelial Lesions (Vulvar HSIL)
Latest Information Update: 25 Dec 2024
Price :
$35 *
At a glance
- Drugs Artesunate (Primary)
- Indications Squamous cell cancer; Vulvar intraepithelial neoplasia
- Focus Therapeutic Use
- Acronyms ART-VIN IIB
- Sponsors Frantz Viral Therapeutics
- 19 Dec 2024 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.
- 19 Dec 2024 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2025.
- 06 Dec 2023 Planned primary completion date changed from 1 Oct 2024 to 1 Dec 2024.